A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Trial Profile

A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs GSK 2857916 (Primary)
  • Indications Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Acronyms DREAMM-1
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Mar 2018 Planned primary completion date changed from 4 Apr 2018 to 29 Jun 2018.
    • 22 Mar 2018 Planned primary completion date changed from 28 Mar 2018 to 4 Apr 2018.
    • 22 Feb 2018 Planned End Date changed from 1 Jun 2020 to 9 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top